Sanofi’s Multaq Doubled Deaths From Heart Disease in Study

Sanofi’s Multaq, approved to treat patients whose hearts intermittently race with quick and inefficient contractions, doubled the risk of death in those with a permanent form of the erratic rhythm, a study found.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.